Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces to make a diversified and scaled biopharmaceutical institution focused connected the cardinal tense strategy (CNS).

Through this all-stock merger, which is expected to make pro forma nett gross of $2.2bn, the duo volition wed their commercialized portfolios, which see 11 medicines spanning the realm of neurology, addiction and psychiatry.

Supernus' products see respective approved therapeutics - ADHD medication, Qelbree (viloxazine hydrochloride) and Parkinson's illness drug, Gocovri (extended-release amantadine), which became the company's best-selling assets by bringing successful $72.8m and $21.9m successful nett merchandise income during the archetypal six months of 2026. Also successful Supernus' portfolio are drugs for postpartum slump treatment, cervical dystonia, epilepsy and migraine.

Meanwhile, Indivior volition bring its postulation of OUD treatments to the table. This includes injectable OUD therapy, Sublocade (extended-release buprenorphine), which pulled successful $856m successful 2025 – up 13% from the erstwhile year. Also successful Indivior's portfolio are sublingually administered therapies similar Suboxone (buprenorphine and naloxone) and exigency opioid overdose-curbing nasal spray, Opvee (nalmefene).

According to the companies, this merger volition make a differentiated portfolio of medicines incorporating respective cardinal maturation products, portion allowing the entity to turn its commercialized portfolio, beforehand its pipeline and uncover caller concern improvement opportunities. They besides expect the woody to make astir $125m successful expected yearly outgo synergies.

If the merger goes done arsenic expected successful the 4th fourth of 2026, existent Supernus founder, CEO and president, Jack Khattar, volition instrumentality the helm arsenic the caller entity's main executive, which volition commercialized nether the sanction Supernus Inc and stay connected the Nasdaq speech nether the ticker 'SUPN'. Khattar primitively founded Supernus successful 2005, and has served arsenic president, manager and CEO of the institution ever since.

On the advisory side, Indivior non-executive manager and anterior Biogen and Scholar Rock executive, Tony Kingsley, volition service arsenic the seat of Supernus Inc's board, which volition dwell of 4 members from each founding company.

In an capitalist call, some companies noted that, moving forward, CNS would stay a cardinal absorption for the business, though the brace are besides funny successful pursuing women's health. Executives added that improvement of mid-to-late-stage assets is besides a apical precedence for the combined business.